Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024
23 Sep, 2014, 18:16 BST
DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024" report to their offering.
Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.
The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature.
Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.
As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.
The Antibody Drug Conjugates Market (2nd edition), 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.
One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analyzing:
- Products currently available in the market and those under development (both clinical / pre-clinical),
- Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs,
- Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,
- Competitive landscape and inherent threats to growth in the short and long term,
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND
5. ADC MARKET FORECAST, 2014 - 2024
6. MANUFACTURING OF ADCs
7. RECENT DEVELOPMENTS: FOCUS ON PARTNERSHIPS AND TECHNOLOGY EVOLUTION
8. PROFILES OF LEADING COMPANIES
9. SWOT ANALYSIS
10. INTERVIEW TRANSCRIPTS
11. CONCLUSIONS
12. APPENDIX 1: TABLES
13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
Companies Mentioned:
- 5AM Ventures
- Abbott
- AbbVie
- Abgenix
- AbGenomics
- Abzena
- Acceleris Capital
- ADC Biotechnology
- ADC Therapeutics
- Adimab
- Affinicon
- Agensys
- Albany Molecular Research, Inc. (AMRI)
- Allozyne
- Alpha Cancer Technologies
- Alta Partners
- Ambrx
- Amerisource Bergen Corporation
- Amgen
- Amgen Ventures
- Antitope
- Apposite Capital
- Aravis General Partner
- Astellas Pharma
- AstraZeneca
- Avid Biologics
- Baxter BioPharma Solutions
- Bayer Healthcare
- biOasis Technologies
- Biocon
- BioInvent International
- Biotecnol
- Biotest
- BioXpress Therapeutics
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BSP Pharmaceuticals
- Cambrex Corporation
- Cape Family Fund LLC
- Carbogen Amcis
- Cardinal Health, Inc
- Catalent Pharma Solutions
- Celldex Therapeutics
- Celltrion
- Celtic Therapeutics Holdings
- Chugai Pharmaceuticals
- CMEA Capital
- CuraGen
- CytomX Therapeutics
- Cytovance Biologics LLC
- Daiichi Sankyo
- Dendreon Corporation
- Dong-A Pharmaceutical
- DSM Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Endocyte
- Esperance Pharmaceuticals
- Fidelity Biosciences
- Fujifilm Diosynth Biotechnologies
- Genentech
- Genmab
- Glycotope
- Goodwin Biotechnology
- GSK
- Hanwha Chemical
- Harris and Harris Group
- Heidelberg Pharma
- Igenica
- ImmunoGen
- Immunomedics
- Intellect Neurosciences
- ISU Abxis
- Janssen Cilag
- Johnson & Johnson
- Lansing Brown Investments LLC
- Laureate Biopharmaceutical Services
- Lilly Ventures
- Lonza
- MacroGenics
- Maverick Capital
- McKesson Corporation
- Medarex
- MedImmune
- Medivation
- Meiji Seika Pharma
- Menarini Group
- Merck
- Merck KGaA
- Mersana Therapeutics
- Micromet
- Millennium
- Mylan
- NBE Therapeutics
- New Enterprise Associates
- Nippon Kayaku
- Novartis
- Novasep
- Oxford BioTherapeutics
- Pfizer
- Pfizer Venture Investments
- Philochem
- PhotoBiotics
- Pierre Fabre Medicament Production
- Piramal Healthcare Pharma Solutions
- PlantForm Corporation
- Polytherics
- Progenics Pharmaceuticals
- ProQuest Investments
- PureTech Ventures
- Redwood Bioscience
- Rho Ventures
- Roche
- Sanofi Aventis
- Seattle Genetics
- Shanghai CP Guojian
- Sigma Aldrich Fine Chemicals (SAFC)
- Skyline Ventures
- SocietàItalianaCorticosteroidiS.r.l
- Spirogen
- Stem CentRx
- Sumitomo Pharmaceuticals
- Sutro Biopharma
- SV Life Sciences
- SynAffix
- Synthon
- Takeda Pharmaceuticals
- Tavistock Life Sciences
- ThioLogics
- TUBE Pharma
- UCB Pharma
- Ventana Medical Systems
- Versant Ventures
- VIVENTIA Biotechnologies
- Watson Pharmaceuticals
- Wilex
- Wyeth
- Zhejiang Medicine Co. Ltd. (ZMC)
For more information visit http://www.researchandmarkets.com/research/6vc6gm/antibody_drug
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
SOURCE Research and Markets